Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for PetVivo Holdings, Inc. (PETVW warrants, PETV common stock) provides direct access to the company’s official regulatory disclosures. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information about corporate events, governance changes, investor communications and financial presentations that are relevant to understanding the business underlying the PETVW warrants.
Recent Form 8-K filings illustrate how PetVivo reports material events. For example, one Form 8-K describes the appointment of an independent director to the board and the expansion of the board’s size, while another notes the resignation of a director and a corresponding reduction in the number of board seats. Other 8-K filings furnish investor presentations under Regulation FD, making slide decks and related materials part of the public record without treating them as filed for liability purposes.
Through its filings, PetVivo identifies itself as a Nevada corporation with a specific Commission File Number and employer identification number, and it provides its corporate telephone contact. These documents complement the company’s news releases that describe its focus on manufacturing, commercialization and licensing of veterinary medical devices and therapeutics for companion animals and horses, as well as its AI initiatives via PetVivo AI, Inc. and the PetVivo.ai platform.
On Stock Titan, this filings page is updated as new PetVivo documents are posted to the SEC’s EDGAR system, enabling users to review 8-Ks, investor presentations and other reports in one place. AI-powered tools can help summarize key points from lengthy filings, highlight sections related to board composition, strategic agreements or investor communications, and make it easier to connect these disclosures with the performance of the underlying PETVW warrants.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Robert James Rudelius purchased 50,000 shares of restricted common stock in a private sale. On April 15, 2026, he bought these shares from another PetVivo shareholder at $0.40 per share, bringing his direct holdings to 403,392 common shares. He also reports indirect ownership of 21,000 common shares held by a corporation.
PetVivo Holdings, Inc. closed the final tranche of a private equity financing on April 15, 2026, receiving $600,000 and bringing the total investment under a Subscription Agreement to $1,000,000. The Company issued 1,250,000 units at $0.80 per unit, each unit containing one restricted common share and a warrant to buy one common share at $1.10. The warrants are exercisable immediately and expire three years from issuance. The investor also received an option to purchase up to an additional $1,500,000 of equity on similar terms, for up to 1,875,000 more units, which the Company anticipates could be funded on or before June 15, 2026. The transaction was structured as a private placement to an accredited investor under Section 4(a)(2) and Regulation D, and all securities issued are characterized as restricted.
PetVivo Holdings, Inc. disclosed that A.L. Sarroff Fund, LLC, a ten percent owner, made open-market purchases of its common stock. The fund bought a total of 24,033 shares on March 23, 2026, including 23,033 shares at $0.68 and 1,000 shares at $0.7499 per share. Following these transactions, the fund directly holds 10,202,229 common shares, with Alan L. Sarroff deemed to beneficially own and exercise sole voting and dispositive power over these securities.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Robert James Rudelius received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 353,392 common shares. He also has an additional 21,000 shares reported as indirectly held through a corporation. This Form 4 reflects a compensation-related share grant rather than an open-market purchase or sale.
Ruben Joshua David reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Ruben Joshua David reported stock-based compensation grants. He received an aggregate annual grant of 46,332 restricted common shares for Board service, vesting in four installments: 8,832 shares for the pro-rated first quarter and 12,500 shares at the beginning of each subsequent quarter of service.
He also received a one-time grant of 7,500 restricted shares as compensation for prior Board service. Following these awards, he holds 53,832 common shares directly. These are compensation-related grants, not open-market purchases or sales.
PetVivo Holdings, Inc. director Diane M. Levitan reported an acquisition of 15,000 shares of common stock at $0.74 per share. The transaction is coded as a grant or award, meaning these shares were received as compensation rather than bought in the open market.
According to a footnote, this is a one-time grant of 15,000 restricted common shares as compensation for prior Board service. Following this award, Levitan directly owns 71,489 shares of PetVivo common stock.
Jasper Joseph William reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Jasper Joseph William received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 135,159 common shares, with an additional 2,000 shares held indirectly by his wife. This is a compensation-related equity grant, not an open-market purchase.
Costantino Robert J reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that director Robert J. Costantino received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service. The grant, valued at $0.74 per share for reporting purposes, increases his direct holdings to 108,661 shares of common stock.
PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.
The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.
LOWENTHAL GARRY N reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. granted 71,993 shares of restricted common stock at $0.69 per share to a corporation owned by Chief Financial Officer Garry N. Lowenthal as compensation for past performance. These shares are held indirectly, bringing his reported indirect holdings to 812,460 shares.